Regulatory Update on Advanced Therapy Products in Hong Kong
Content

• **What** is ATP?

• **Regulation** of ATP
  - Pharmacy and Poisons (Amendment) Ordinance 2020

• **Scope** of ATP Regulation
  - Classification of ATP
  - Record Keeping
  - Labelling
  - Manufacture
  - ADR reporting
  - Import & Export
  - Product Registration
  - Clinical Trial
What is Advanced Therapy Product?

- ATPs* are innovative medicinal products based on genes, cells and tissues.
- Scientific advancement in ATP may offer great medical potential.
- Risks and long-term side effects need to be carefully managed due to their complicated nature and the limited knowledge about these products.

* The exact legal definition of “Advanced Therapy Product” is set out in the section 2 of the Pharmacy and Poisons Ordinance (Cap. 138), which is available at https://www.elegislation.gov.hk
Regulation of Cells & Tissues Products

Risk-based Approach

Separate Regulatory Framework
Guidelines & Standards

Low Risk
- Minimal
- Homologous use

High Risk
- Substantial manipulation
- Non-homologous use

Advanced Therapy Products
- Somatic Cell Therapy Products
- Tissue Engineered Products
- Gene Therapy Products

Pharmaceutical Products under the PPO

Cell and Tissue for Human Application

Pharmacy and Poisons (Amendment) Ordinance 2020

Contents

Section Page

Part 1

Preliminary
1. Short title and commencement.................................... A1639
2. Enactments amended................................................. A1639

Part 2

Amendments to Pharmacy and Poisons Ordinance (Cap. 138)

3. Section 2 amended (interpretation)............................. A1641
4. Section 38 and Schedule added.................................. A1640
5. Amendment of Schedule........................................... A1640

Schedule Manipulation Processes that are Not Substantial Manipulations ........ A1640

Part 3

Amendments to Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A)

6. Regulation 2 amended (interpretation)......................... A1653
7. Regulation 22 amended (supply of medicines to out-patients from certain institutions, etc.).......................... A1653
8. Regulation 28 amended (records to be kept by licensed wholesale dealers or licensed manufacturers)................ A1655
9. Regulation 31 amended (labelling by licensed manufacturers).......................................................... A1655
10. Regulation 35 amended (duties of licensed manufacturers regarding identity, purity, safety, etc.)......................... A1657
11. Regulation 35 amended (records to be kept by licensed manufacturers).................................................. A1659
12. Regulation 36 amended (registration of pharmaceutical products and substances)....................................... A1663
13. Regulation 39 amended (period of keeping of records)...... A1663
14. Regulation 40 amended (penalties)............................. A1667

Pharmacy and Poisons (Amendment) Ordinance 2020

Amendment Ordinance

• Amended Pharmacy and Poisons Ordinance to regulate ATP
• Passed by LegCo and gazetted in July 2020
• Come into operation on 1 August 2021

Relevant Guidance

Regulation of Advanced Therapy Products

- Pharmacy and Poisons (Amendment) Ordinance 2020
- Guidance for Industry
  - Classification of Advanced Therapy Products
  - Manufacture
  - Drug Registration
  - Clinical Trial
  - Import and Export
  - Labelling of Advanced Therapy Product
  - Record Keeping
  - Adverse Drug Reaction Reporting
  - Other Guidance applicable to Pharmaceutical Products
- Guidance for Healthcare Professionals
  - Classification of Advanced Therapy Products
  - Record Keeping
  - Adverse Drug Reaction Reporting
  - Clinical Trial
  - Import for the Treatment of a Particular Patient
- List of Registered Advanced Therapy Products

Available at
Classification of ATP
Classification of ATP

To include ATP in PP Definition (S.2)

Existing

*pharmaceutical product* (藥劑製品) and *medicine* (藥物) mean any substance or combination of substances—

(a) presented as having properties for treating or preventing disease in human beings or animals; or

(b) that may be used in, or administered to, human beings or animals, either with a view to—

(i) restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action; or

(ii) making a medical diagnosis;

Amended Version

*pharmaceutical product* (藥劑製品)—

(a) means a substance or combination of substances that—

(i) is presented as having properties for treating or preventing disease in human beings or animals; or

(ii) may be used in or administered to human beings or animals with a view to—

(A) restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action; or

(B) making a medical diagnosis; and

(b) includes an *advanced therapy product*;

*medicine* (藥物) has the same meaning as in the definition of *pharmaceutical product*;
Classification of ATP

Definition of ATP (S.2)

New Provision

"Advanced therapy product" (先進療法製品) means any of the following products that is for human use—

(a) a gene therapy product;
(b) a somatic cell therapy product;
(c) a tissue engineered product;
Classification of ATP

Definition of Gene Therapy Product (S.2)

*New* Provision

Gene therapy product (基因療法製品)—

(a) means a product—

(i) that contains an active substance containing or consisting of a *recombinant nucleic acid* that may be used in or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a *genetic sequence*; and

(ii) the *therapeutic*, *prophylactic* or *diagnostic effect* of which relates directly to—

(A) the recombinant nucleic acid *sequence* it contains; or

(B) the *product* of *genetic expression* of that sequence; but

(b) does not include a *vaccine against an infectious disease*
Classification of ATP

Definition of Somatic Cell Therapy Product (S.2)

New Provision

Somatic cell therapy product (體細胞療法製品) means a product that—

(a) contains or consists of any of the following cells or tissues—
   (i) cells or tissues that have been subject to substantial manipulation so that their biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered;
   (ii) cells or tissues that are not intended to be used for the same essential functions in their recipient as in their donor; and

(b) is presented as having properties for, or may be used in or administered to human beings with a view to—
   (i) treating, preventing or diagnosing a disease; or
   (ii) restoring, correcting or modifying physiological functions,

through the pharmacological, immunological or metabolic action of those cells or tissues

Cells or tissues  Two Factors  Presentation and Mechanism of Action
(1) Substantial manipulation [(a)(i)] OR
(2) Not for the same essential function [(a)(ii)]
**Classification of ATP**

**Definition of Tissue Engineered Product (S.2)**

**New Provision**

Tissue engineered product (組織工程製品)—

(a) means a product that—

(i) contains or consists of any of the following cells or tissues—

(A) cells or tissues that have been subject to **substantial manipulation** so that their biological characteristics, physiological functions or structural properties relevant for the **intended regeneration, repair or replacement** have been altered;

(B) cells or tissues that are **not intended to be used for the same essential functions** in their recipient as in their donor; and

(ii) is presented as having properties for, or may be used in or administered to human beings with a view to, **regenerating, repairing or replacing** a human tissue; but

(b) does **not include** a product that—

(i) contains or consists of **exclusively non-viable** human or animal cells or tissues; and

(ii) does **not act principally by pharmacological, immunological or metabolic action**

---

**Cells or tissues**

**Two Factors**

1. Substantial manipulation [(a)(i)(A)] **OR**
2. Not for the same essential function [(a)(i)(B)]

**Presentation and Mechanism of Action [(a)(ii)]**
Classification of ATP

Schedule for “Non-substantial” Manipulation

New Provision

S.2 substantial manipulation (實質處理), in relation to cells or tissues, does not include the manipulation processes set out in the Schedule;

Schedule

Manipulation Processes that are Not Substantial Manipulations

1. Cutting
2. Grinding
3. Shaping
4. Centrifugation
5. Soaking in antibiotic or antimicrobial solutions
6. Sterilization
7. Irradiation
8. Cell separation, concentration or purification
9. Filtering
10. Lyophilization
11. Freezing
12. Cryopreservation
13. Vitrification

S.38 Amendment of Schedule

The Director of Health may, by notice published in the Gazette, amend the Schedule.
Definition of ATP

Guidance on Classification of ATP

Guidance on Classification of Advanced Therapy Products

Version 1.0
Pharmacy and Poisons Board of Hong Kong

Record Keeping
Record Keeping

- Aim to ensure **traceability**
- To require retention of record on
  - **Distribution**
  - **Practitioner** responsible for use of product for **30 years** after expiry date
- Provisions for **bankruptcy/wound up/dissolution** and **cessation** of licence
  - Transfer specified documents to **Pharmacy and Poisons Board** within specified timeframes
- **Guidance** to **Medical Practitioners, Dentists** and **Institutions**
Guidance on Record Keeping for Licensed Manufacturers and Licensed Wholesale Dealers

- Advanced Therapy Products

Version 1.0
Pharmacy and Poisons Board of Hong Kong

Can be found at
Record Keeping

Transaction Records by WDL and ML
(Section 5 of the Guidance)

• Required under regulation 28 of the PPR

• Record of particulars of acquisition (r. 28(1)) and disposal (r.28(2)) of PPs (including ATPs) and Poisons

(a) the date of the transaction;
(b) the name of the supplier;
(c) the name of the poison or pharmaceutical product;
(ca) the batch number, pack size and unit of quantity of the poison or pharmaceutical product;
(d) the total quantity of the poison or pharmaceutical product;
(e) the nature of the transaction; and
(f) a reference to the invoice or other documents supporting the transaction.

(a) the date of the transaction;
(b) the nature of the transaction;
(c) the name of the person to whom the poison or pharmaceutical product is supplied;
(ca) for an ATP supplied for use by a registered medical practitioner or registered dentist – the name and address of the practitioner or dentist;
(d) the total quantity of the poison or pharmaceutical product;
(e) a reference to the invoice or other documents supporting the transaction;
(f) the name of the poison or pharmaceutical product;
(fa) the batch number, pack size and unit of quantity of the poison or pharmaceutical product;
(g) the balance of the poison or pharmaceutical product remaining in his possession after the transaction.

• Same requirement as other PPs, except
  • r. 28(2)(ca) for disposal of ATPs
  • Duration – 30 years after the expiry date of the product
  • Transfer to the Board if cessation of operation (Section 6 of the Guidance)

* ML should also refer to requirements in the GMP Guide if applicable.
Labelling
Labelling of ATPs with
- Product code
- Unique donation identifier (UDI)
  - For autologous product
    - Unique recipient identifier (URI)
    - “For autologous use only” or “只供自體使用”
- Code and Identifiers assigned according to Code of Practice
- International recognized systems
  - ISBT 128 standard
  - Single European Code (SEC)
Labelling

Guidance on Labelling Requirements of Product Code, UDI and URI for ATP

Guidance on Labelling Requirements of Product Code, Unique Donation Identifier and Unique Recipient Identifier for Advanced Therapy Products

Version 1.0
Pharmacy and Poisons Board of Hong Kong

CONTENTS

1. Introduction .............................................................................................................. 3
2. Purpose and Scope .................................................................................................. 5
3. Internationally Recognized Systems ...................................................................... 6
4. Requirements of Product Code ............................................................................. 10
5. Requirements of Unique Donation Identifier ...................................................... 13
6. Requirements of Unique Recipient Identifier for Autologous Advanced Therapy Products .............................................................. 16
Document Information ................................................................................................. 17

Can be found at
Labelling

**Product Code & Unique Donation Identifier**

- **Product Code**
  - Coding sequence for *identification* of *cell and tissue types* contained in an ATP

- **Unique Donation identifier (UDI)**
  - Unique sequence attributed to *specific donation* of cells or tissues for unique identification

- Two widely accepted coding systems for *human* cells and tissues
  - **ISBT 128** by ICCBBA
  - **Single European Code (SEC)** – for EU
  - Both systems include two components – **Product Code + UDI**

- For ATPs containing *human* cells or tissues
  - Either **ISBT 128** or **SEC** could be used to meet both the Product Code and UDI requirement
  - If **NOT**, assigned according to **section 4 (Product Code)** and **section 5 (UDI)** of the Guidance
Labelling

Unique Recipient Identifier (URI)

- Applies **only** to ATPs for **autologous use** *
- **Combination** of **recipient information** sufficient for healthcare professionals to verify the **identity** of the intended recipient
- URI should consist of at least **2 sets** of information
  - either
    - Recipient’s **surname** followed by **initials** of first name + Number/sequence referring to the recipient (e.g. part of recipient’s hospital no. /medical record no.)
    - Month and year of birth
- Example:
  - Name of Recipient: ChanTM
  - Month and Year of Birth: 01/1960
- Should ensure HCP fully understand **how to interpret** and use the URI to verify the identity of the recipient
- Should comply with the Personal Data (Privacy) Ordinance (Cap. 486) requirements
  - * ATPs for autologous use should also be labelled with “**For autologous use only**” or “只供自體使用”
Manufacture
• **Manufacturing Licence** is required for **ALL** facilities
  • that involve **substantial manipulation** of cells or tissues in production process, including **institutions**
  • for the production of **GTP**
  • for **affixing** to the container of ATP a **label** stating –
    • **Product code**
    • **Unique donation identifier (UDI)**
    • **Unique recipient identifier (URI)**
    • “For autologous use only” or “只供自體使用”

* Licence for Manufacturer (Secondary Packaging) if **only involves** labelling, re-labelling, cartoning, re-cartoning or adding additional information to PP which are already enclosed in the container in which they are to be sold or supplied.
ADR Reporting
• **Existing** requirements to report ADR

• **Guidance** for **industry** & HCP
  
  • **Industry**
  
  • to **report** all serious OR unexpected ADR

• **Traceability**
  
  • Include the **Batch number**
  
  • System in place capable of linking ADR reports with other traceability data

• **List** of potential **ADR of concern**


---

Guidance for Pharmaceutical Industry - Adverse Drug Reaction Reporting Requirements

Version 1.0
Pharmacy and Poisons Board of Hong Kong

Guidance for Healthcare Professionals – Adverse Drug Reaction Reporting

Version 2.0
Drug Office
Department of Health
Guidance for Pharmaceutical Industry - Adverse Drug Reaction Reporting Requirements

Version 1.0
Pharmacy and Poisons Board of Hong Kong
Guidance for Healthcare Professionals – Adverse Drug Reaction Reporting

Version 2.0

Drug Office
Department of Health

ADRs Reporting
Guidance for Healthcare Professionals – Adverse Drug Reaction Reporting

CONTENTS

1. Introduction ................................................................. 3
2. What is Adverse Drug Reaction? .................................. 4
   2.1 Adverse Drug Reaction ........................................ 4
   2.2 Serious Adverse Drug Reaction .............................. 4
   2.3 Unexpected Adverse Drug Reaction ....................... 4
3. Where to Get the Report Form? .................................. 5
   4.1 Special Considerations for Advanced Therapy Products 6
5. What should be Included in the Report? ....................... 8
   5.1 Follow-up Reports ................................................ 10
7. What Happen to the Report? ........................................ 11
8. Contact for Further Information .................................... 12
 Appendix 1 DH Do Adverse Drug Reaction Report Form .......... 13
 Appendix 2 Definitions of Gene Therapy Products, Somatic Cell Therapy Product and Tissue Engineered Products .................... 16
 Appendix 3 Sample of Label containing ISBT 128 Code .......... 19
 Appendix 4 Sample of Label containing Single European Code (SEC) ........ 20
 Appendix 5 Statement of Purposes ................................. 21
 Document Information .................................................. 22
6.1 Potential Adverse Drug Reactions of Concern

Some potential adverse drug reactions of concern are listed below. Nevertheless, not all of the adverse drug reactions listed below are unique to ATPs. The list serves to provide examples to stimulate further considerations.

- Adverse drug reactions related to quality characteristics of the product
  - Transmission of diseases (e.g. viral, bacterial or parasitical infections and infestations) in relation to the origin of cells or tissues
  - Tumourigenesis due to the alteration of differentiation capacity of the cells during the manufacturing process, "off target" mutations and unintended "on target" mutations in relation to gene editing, etc.

- Adverse drug reactions related to the storage and distribution of the product
  - Treatment failure due to impact on the biologic activity in relation to preservation, freezing and thawing and breaking the controlled temperature conditions

- Adverse drug reactions related to patient associated conditions/disease or underlying disease, or concomitant treatment/interactions with other medicinal products
  - Unwanted immunogenicity and the consequences
  - Adverse drug reactions related to conditioning of patient, e.g. chemotherapy in case of CAR T-cell therapy
  - Adverse drug reactions related to both intended and unintended genetic modification of the patient's cells

- Early and late consequences of homing, grafting, differentiation, migration and proliferation
- Infection with vectors used in gene therapy medicinal products
- Adverse drug reactions related to clinical follow-up, e.g. immunosuppression associated with the co-medication

- Adverse drug reactions related to reconstitution procedures
- Dosing errors and maladministration

- Adverse drug reactions related to administration procedures and re-administration

- Adverse drug reactions related to persistence of the product in the patient
  - Later complications (e.g. malignancies and autoimmunity)
  - Adverse drug reactions related to non-specific integration into other cells with the potential of tumourigenicity
  - Adverse drug reactions related to germ line integration of transgene or other genetic transformation of the germ line

- Transmission of virus or vector to healthcare professionals, care givers, offspring and other close contacts

- Adverse drug reactions occurring in offspring due to:
  - Foetal transmission of vectors, biologically active substances, cells, infectious agents, etc.
  - Transmammary exposure of children for lactating women (to vectors, biologically active substances, cells, infectious agents, etc.)
Import & Export
Import/Export

• **Same** requirements as other **pharmaceutical products + Considerations** specific to **ATPs**

• Requires an **Import/Export licence** to import/export of pharmaceutical products
  • Under the Import and Export Ordinance, (Cap. 60)

• Person carrying on **business** as an **importer** or **exporter** of PP –
  • **Licensed wholesale dealer** or
  • **Licensed manufacturer** (import for own manufacturing or export of own manufactured product)
Import/Export

Guidance on Application of Import and Export Licences – Advanced Therapy Products

Version 1.0

Drug Office
Department of Health

Scope of the Guidance

- **Registered** ATPs
- **Unregistered** ATPs for –
  - Clinical Trial: Same as other PPs – Requires a certificate for clinical trial/medicinal test
  - Treatment of a particular patient
  - Re-export: Same as other PPs
- **Starting** and **raw materials** for ATP **manufacturing**
- **Other relevant legislations**
# Import/Export

## Other relevant Legislation
(Section 9 of the Guidance)

<table>
<thead>
<tr>
<th>Subject Matter</th>
<th>Materials</th>
<th>Examples</th>
<th>Legislation</th>
<th>Responsible Department/Office</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infectious agents</strong></td>
<td>Biological materials containing or consisting of or suspected to be containing of infectious agents (e.g. viral vectors)</td>
<td>Viral Vector</td>
<td>Prevention and Control of Disease Regulation (Cap. 599A)</td>
<td>Port Health Division of Department of Health</td>
<td><a href="https://www.dh.gov.hk/english/main/main_ph/main_ph.html">https://www.dh.gov.hk/english/main/main_ph/main_ph.html</a></td>
</tr>
<tr>
<td><strong>Animal Products (Rabies)</strong></td>
<td>Materials containing or consisting of parts or derivative of a dog, a cat or any animal that has been infected with rabies</td>
<td>Dog skin, canine plasma</td>
<td>Rabies Regulation (Cap. 421A)</td>
<td>Agriculture, Fisheries and Conservation Department (AFCD)</td>
<td><a href="https://www.afcd.gov.hk/english/quarantine/quai_ei/quai_ei.html">https://www.afcd.gov.hk/english/quarantine/quai_ei/quai_ei.html</a></td>
</tr>
<tr>
<td>Genetically Modified Organisms (GMO)</td>
<td>Starting and raw materials containing or consisting of GMOs * Not applicable to GMO that is a PP for use by human being</td>
<td>GM viral vector</td>
<td>Genetically Modified Organisms (Control of Release) Ordinance (Cap. 607)</td>
<td>Agriculture, Fisheries and Conservation Department (AFCD)</td>
<td><a href="https://www.afcd.gov.hk/english/conservation/con_gmo/con_gmo.html">https://www.afcd.gov.hk/english/conservation/con_gmo/con_gmo.html</a></td>
</tr>
</tbody>
</table>
Product Registration
Guidance on Application of Certificate of Drug/Product Registration — Advanced Therapy Products

Version 1.0
Pharmacy and Poisons Board of Hong Kong

Can be found at
Product Registration

Requirements specific to ATPs

- Registration approval of the product in two or more of the following countries* –
  - Australia, Austria, Belgium, Bulgaria, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holland, Hungary, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, UK and USA

  * Approval from the EU countries must be issued from EMA

- Submission of ICH CTD Modules 2 – 5
  - Specific requirements to ICH CTD Modules 3 (Quality), 4 (Nonclinical) and 5 (Clinical) in Appendices 1 – 3 of guidance

- Description of traceability system
  - Bidirectional traceability from donor to medical practitioner/dentist using the ATP and vice versa

- Product label
  - Should comply with “Guidance on Labelling Requirements of Product Code, Unique Donation Identifier and Unique Recipient Identifier for ATPs”
  - Should specify the coding system adopted
Product Registration

Regulated Product under HOTO

- “Organ” is subject to the regulatory control under Human Organ Transplant Ordinance (Cap. 465) (HOTO), including the prohibition of commercial dealings.

- The Director of Health may, on application, exempt a regulated product from the application of the whole or any part(s) of the HOTO if certain criteria have been met.

Section 7A of HOTO

Regulated product (受規管產品) means a product containing any structured arrangement of tissues that—
(i) falls within paragraph (a)(iii) of the definition of organ in section 2; and
(ii) has been subjected to processing.

Processing (加工處理), in relation to any structured arrangement of tissues, means any activity performed on the tissues which alters the biological characteristics, function or integrity of the tissues, but does not include recovering or preparing the tissues, preserving the tissues for storage, or removing the tissues from storage.

- If an ATP falls within the definition of “regulated product” in HOTO, the application dossier for exemption may be submitted to Drug Office together with product registration.

- For details of application for exemption of regulated product, please refer to DH website.
Clinical Trial
Guidance on Application of Certificate for Clinical Trial

Guidance on Application of Certificate for Clinical Trial - Advanced Therapy Products

Version 1.0
Pharmacy and Poisons Board of Hong Kong

Can be found at
Clinical Trial

Considerations specific to ATPs

- **Traceability**
  - Ensure **bidirectional** traceability **from donor to subject** and **from subject to donor**
  - **Sponsor** should –
    - Ensure that the **manufacturer** has set up a **system** that enables bidirectional tracking of cells or tissues contained in ATPs
    - Provide the **investigator** with detailed **instructions** to ensure traceability
  - Data should be kept for **30 years** after the expiry date of the product

- **Informed consent**
  - Where applicable, **subject** should be **informed** of –
    - Irreversible nature of ATP
    - Risk to close contacts and off-springs
    - If the treatment could compromise future pregnancies
    - The need for long-term follow-up and seeking subject commitment

- **Long-term follow-up**
  - **Scheme** for long-term follow-up where applicable
Thank You